Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention

NCT01888575 COMPLETED

This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained .The aims of the post hoc analyses are: To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use, crude and adjusted by confounding. To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex. To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy.

Details

Lead sponsor	AstraZeneca
Status	COMPLETED
Enrolment	35604
Start date	2012-09
Completion	2013-06

Conditions

• Cardiovascular Prevention

Interventions

• Risk of low dose aspirin discontinuation

Primary outcomes

• Risk of low dose ASA discontinuation associated with continuous PPI use vs.non-use — Up to 1 year.
  Risk (hazard ratios) of low dose ASA discontinuation associated with continuous PPI use vs. non-use.
• Risk of low dose ASA discontinuation associated with baseline gastrointestinal risk category ( high risk versus low risk) — Up to 1 year
  Risk ( hazard ratios) of low dose ASA discontinuation associated with baseline gastrointestinal risk category( high risk versus low risk).

Countries

Spain